IGEN keeps up Origen court battle as Roche drops suit
This article was originally published in Clinica
IGEN International has said that it will maintain its Maryland court litigation against Roche Diagnostics over breaches of the licensing agreement for IGEN's proprietary Origen diagnostic detection technology. The company confirmed it was keeping up its action just as Roche agreed to dismiss its Delaware patent suit against IGEN, and agreed to reimburse IGEN's legal fees incurred in defending the suit. These amount to some $5.7 million.